These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27908448)

  • 1. Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis.
    Navarini AA; Hruz P; Berger CT; Hou TZ; Schwab C; Gabrysch A; Higgins R; Frede N; Padberg Sgier BC; Kämpe O; Burgener AV; Marquardsen F; Baldin F; Bigler M; Kistner A; Jauch A; Bignucolo O; Meyer B; Meienberg F; Mehling M; Jeker LT; Heijnen I; Daikeler TD; Gebbers JO; Grimbacher B; Sansom DM; Jeker R; Hess C; Recher M
    J Allergy Clin Immunol; 2017 Mar; 139(3):1043-1046.e5. PubMed ID: 27908448
    [No Abstract]   [Full Text] [Related]  

  • 2. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
    Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
    Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4.
    Lee S; Moon JS; Lee CR; Kim HE; Baek SM; Hwang S; Kang GH; Seo JK; Shin CH; Kang HJ; Ko JS; Park SG; Choi M
    J Allergy Clin Immunol; 2016 Jan; 137(1):327-330. PubMed ID: 26478010
    [No Abstract]   [Full Text] [Related]  

  • 4. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis.
    Ibraheim H; Baillie S; Samaan MA; Abu-Sbeih H; Wang Y; Talley NJ; P Jones M; Powell N
    Aliment Pharmacol Ther; 2020 Nov; 52(9):1432-1452. PubMed ID: 32920854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.
    Zoet ID; de Boer NK; de Meij TG
    J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of Vedolizumab in Immune Checkpoint Inhibitor-associated Enterocolitis.
    Stone ML; Forster EM
    Inflamm Bowel Dis; 2021 Nov; 27(12):e147. PubMed ID: 34244730
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful Treatment of Refractory Lymphocytic Esophagitis With Vedolizumab.
    Beales ILP
    Am J Gastroenterol; 2019 Sep; 114(9):1555-1556. PubMed ID: 31365353
    [No Abstract]   [Full Text] [Related]  

  • 8. Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease.
    Navaneethan U; Edminister T; Zhu X; Kommaraju K; Glover S
    Inflamm Bowel Dis; 2017 Apr; 23(4):E17. PubMed ID: 28296827
    [No Abstract]   [Full Text] [Related]  

  • 9. Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation.
    Wright AP; Fontana RJ; Stidham RW
    Liver Transpl; 2017 Jul; 23(7):968-971. PubMed ID: 28296011
    [No Abstract]   [Full Text] [Related]  

  • 10. Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Coltoff A; Lancman G; Kim S; Steinberg A
    Bone Marrow Transplant; 2018 Jul; 53(7):900-904. PubMed ID: 29371686
    [No Abstract]   [Full Text] [Related]  

  • 11. Crohn's disease with anorectal stenosis successfully treated with vedolizumab.
    Urlep D; Orel R
    World J Pediatr; 2017 Aug; 13(4):394-395. PubMed ID: 28540693
    [No Abstract]   [Full Text] [Related]  

  • 12. Abatacept is useful in autoimmune cytopenia with immunopathologic manifestations caused by CTLA-4 defects.
    Dhunputh C; Ducassou S; Fernandes H; Picard C; Rieux-Laucat F; Viallard JF; Lazaro E; Hermine O; Jouvray M; Machelard I; Lambilliotte A; Malphettes M; Moshous D; Neven B; Gauthier A; Garnier N; Leblanc T; Landman-Parker J; Leverger G; Aladjidi N
    Blood; 2022 Jan; 139(2):300-304. PubMed ID: 34714911
    [No Abstract]   [Full Text] [Related]  

  • 13. Vedolizumab as a Novel Treatment for Refractory Collagenous Colitis: A Case Report.
    Cushing KC; Mino-Kenudson M; Garber J; Lochhead P; Khalili H
    Am J Gastroenterol; 2018 Apr; 113(4):632-633. PubMed ID: 29610507
    [No Abstract]   [Full Text] [Related]  

  • 14. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
    Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
    World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab.
    Wichmann A; Krugliak Cleveland N; Rubin DT
    Am J Gastroenterol; 2016 Apr; 111(4):577. PubMed ID: 27125715
    [No Abstract]   [Full Text] [Related]  

  • 16. Vedolizumab for Crohn's disease.
    Mosli MH; Feagan BG
    Expert Opin Biol Ther; 2013 Mar; 13(3):455-63. PubMed ID: 23394379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-α drug failure.
    Sáez-González E; Aguas M; Huguet JM; Nos P; Beltrán B
    Dig Liver Dis; 2018 Apr; 50(4):415-417. PubMed ID: 29397323
    [No Abstract]   [Full Text] [Related]  

  • 18. Vedolizumab Induced Clinical, Endoscopic, and Histological Improvement in Common Variable Immunodeficiency Disease-associated Intestinal Enteropathy.
    Akhtar HJ; Markandey B; Ma C; Ramsewak D; Walsh JC; Jairath V
    Inflamm Bowel Dis; 2020 Mar; 26(4):e22-e23. PubMed ID: 32002555
    [No Abstract]   [Full Text] [Related]  

  • 19. Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.
    Julsgaard M; Kjeldsen J; Bibby BM; Brock B; Baumgart DC
    Gastroenterology; 2018 Feb; 154(3):752-754.e1. PubMed ID: 28988916
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.